The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.
OBJECTIVE
This review covers the role of the Global HIV Vaccine Enterprise (the Enterprise), an alliance of independent organizations committed to development of a safe and effective HIV vaccine. It discusses the history, impact on the field, and future directions and initiatives of the alliance in the context of recent progress in HIV vaccine research and development.


RESULTS
Significant progress has been made in the field since the release of the 2005 Scientific Strategic Plan (the Plan) of the Enterprise. Over the last year, the Enterprise embarked on an impact assessment of the 2005 Plan and the development of the 2010 Plan. Enterprise Working Groups identified key priorities in the field, several of which are discussed in this review, including changing the nature, purpose and process of clinical trials, increasing and facilitating data sharing, and optimizing existing and mobilizing new resources.


CONCLUSIONS
This time is an important moment in HIV vaccine research. New clinical trial and laboratory results have created new opportunities to advance the search for an HIV vaccine and reinvigorated the field. The Enterprise will publish its 2010 Plan this year, providing a framework for setting new priorities and directions and encouraging new and existing partners to embark on a shared scientific agenda.
Global HIV Vaccine Enterprise, New York, New York, USA.
Yegor
Y
Voronin
Amapola
A
Manrique
Alan
A
Bernstein
D016915:AIDS Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods* / Q000639:trends*; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007391:International Cooperation
D016915:AIDS Vaccines